The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Related News Articles

Headline
The House Energy and Commerce Subcommittee on Health today passed the No Surprises Act (H.R. 3630), bipartisan legislation that would prohibit balance billing…
Headline
President Trump intends to nominate Adam Boehler — senior advisor to the Health and Human Services Secretary, Centers for Medicare…
Headline
The House Energy and Commerce Subcommittee on Health tomorrow is scheduled to mark up 10 health-related bills, including the No Surprises Act — bipartisan…
Headline
The Centers for Medicare…
Headline
Health and Human Services Secretary Alex Azar last week announced that Paul Mango will assume the role of deputy chief of staff for policy, a new position…
Blog
Women in rural areas face unique maternal health care challenges, including hospital closures or lack of obstetric services. In this AHA Stat Blog, Jay Bhatt,…